STAT3 and glioblastoma: The transcription factor STAT3 is a driver of the mesenchymal phenotype in GBM (Carro et al., 2010) and, through its anti-apoptotic effects, can also drive resistance to alkylating and targeted therapies (Fan et al., 2020; Tan et al., 2019; Zhao et al., 2016).